chr7-30598809-G-A
Variant summary
Our verdict is Benign. Variant got -7 ACMG points: 2P and 9B. PP3_ModerateBP6BS1BS2
The NM_002047.4(GARS1):c.236G>A(p.Arg79Gln) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000205 in 1,613,750 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_002047.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -7 ACMG points.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
GARS1 | ENST00000389266.8 | c.236G>A | p.Arg79Gln | missense_variant | Exon 2 of 17 | 1 | NM_002047.4 | ENSP00000373918.3 | ||
GARS1 | ENST00000675651.1 | c.236G>A | p.Arg79Gln | missense_variant | Exon 2 of 17 | ENSP00000502513.1 | ||||
GARS1 | ENST00000675693.1 | c.68G>A | p.Arg23Gln | missense_variant | Exon 3 of 18 | ENSP00000502174.1 | ||||
GARS1 | ENST00000675051.1 | c.35G>A | p.Arg12Gln | missense_variant | Exon 2 of 17 | ENSP00000502296.1 | ||||
GARS1 | ENST00000674815 | c.-134G>A | 5_prime_UTR_variant | Exon 2 of 17 | ENSP00000502799.1 | |||||
GARS1 | ENST00000674851 | c.-134G>A | 5_prime_UTR_variant | Exon 3 of 18 | ENSP00000502451.1 | |||||
GARS1 | ENST00000675810.1 | c.223-1138G>A | intron_variant | Intron 1 of 15 | ENSP00000502743.1 | |||||
GARS1 | ENST00000444666.6 | n.236G>A | non_coding_transcript_exon_variant | Exon 2 of 18 | 3 | ENSP00000415447.2 | ||||
GARS1 | ENST00000674616.1 | n.236G>A | non_coding_transcript_exon_variant | Exon 2 of 18 | ENSP00000502408.1 | |||||
GARS1 | ENST00000674643.1 | n.236G>A | non_coding_transcript_exon_variant | Exon 2 of 17 | ENSP00000501636.1 | |||||
GARS1 | ENST00000674737.1 | n.236G>A | non_coding_transcript_exon_variant | Exon 2 of 18 | ENSP00000502464.1 | |||||
GARS1 | ENST00000674807.1 | n.236G>A | non_coding_transcript_exon_variant | Exon 2 of 16 | ENSP00000502814.1 | |||||
GARS1 | ENST00000675529.1 | n.*106G>A | non_coding_transcript_exon_variant | Exon 3 of 18 | ENSP00000501655.1 | |||||
GARS1 | ENST00000675859.1 | n.236G>A | non_coding_transcript_exon_variant | Exon 2 of 15 | ENSP00000502033.1 | |||||
GARS1 | ENST00000676088.1 | n.*106G>A | non_coding_transcript_exon_variant | Exon 3 of 19 | ENSP00000501884.1 | |||||
GARS1 | ENST00000676140.1 | n.236G>A | non_coding_transcript_exon_variant | Exon 2 of 17 | ENSP00000502571.1 | |||||
GARS1 | ENST00000676164.1 | n.236G>A | non_coding_transcript_exon_variant | Exon 2 of 17 | ENSP00000501986.1 | |||||
GARS1 | ENST00000676210.1 | n.236G>A | non_coding_transcript_exon_variant | Exon 2 of 18 | ENSP00000502373.1 | |||||
GARS1 | ENST00000676259.1 | n.236G>A | non_coding_transcript_exon_variant | Exon 2 of 17 | ENSP00000501980.1 | |||||
GARS1 | ENST00000676403.1 | n.236G>A | non_coding_transcript_exon_variant | Exon 2 of 16 | ENSP00000502681.1 | |||||
GARS1 | ENST00000675529.1 | n.*106G>A | 3_prime_UTR_variant | Exon 3 of 18 | ENSP00000501655.1 | |||||
GARS1 | ENST00000676088.1 | n.*106G>A | 3_prime_UTR_variant | Exon 3 of 19 | ENSP00000501884.1 |
Frequencies
GnomAD3 genomes AF: 0.000105 AC: 16AN: 152138Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000882 AC: 22AN: 249462Hom.: 0 AF XY: 0.0000886 AC XY: 12AN XY: 135368
GnomAD4 exome AF: 0.000216 AC: 315AN: 1461612Hom.: 0 Cov.: 31 AF XY: 0.000191 AC XY: 139AN XY: 727120
GnomAD4 genome AF: 0.000105 AC: 16AN: 152138Hom.: 0 Cov.: 32 AF XY: 0.000161 AC XY: 12AN XY: 74318
ClinVar
Submissions by phenotype
not provided Uncertain:3Benign:3
- -
- -
GARS1: BS2 -
- -
The GARS1 c.236G>A; p.Arg79Gln variant (rs369466037) is reported in the literature in an individual affected with Charcot-Marie-Tooth disease, although its clinical significance was not demonstrated (Volodarsky 2021). This variant is found in the non-Finnish European population with an allele frequency of 0.02% (23/128,638 alleles) in the Genome Aggregation Database (v2.1.1). Computational analyses are uncertain whether this variant is neutral or deleterious (REVEL: 0.69). Due to limited information, the clinical significance of this variant is uncertain at this time. References: Volodarsky M et al. Comprehensive genetic sequence and copy number analysis for Charcot-Marie-Tooth disease in a Canadian cohort of 2517 patients. J Med Genet. 2021 Apr;58(4):284-288. PMID: 32376792. -
In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge -
Charcot-Marie-Tooth disease type 2 Uncertain:1
This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 79 of the GARS protein (p.Arg79Gln). This variant is present in population databases (rs369466037, gnomAD 0.02%). This missense change has been observed in individual(s) with Charcot-Marie-Tooth disease (PMID: 32376792). ClinVar contains an entry for this variant (Variation ID: 188197). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is not expected to disrupt GARS protein function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
not specified Benign:1
This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at